Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Solid Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Solid Biosciences Inks Licensing Deal with Kinea Bio for Next-Gen Capsid AAV-SLB101 Use
Details : Kinea Bio will use Solid’s next-generation capsid, AAV-SLB101, for the development of KNA-155, an investigational dual AAV gene therapy.
Product Name : KNA-155
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 23, 2025
Lead Product(s) : KNA-155
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Solid Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement